COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
Las Vega (Nevada), United States // – DelveInsight’s “Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Extensive-Stage Small Cell Lung Cancer Market.
The Extensive-Stage Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
As per DelveInsight’s assessment, globally, about 40+ key pharma and biotech companies are working on 40+ drugs in the Extensive-Stage Small Cell Lung Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of ESCLC and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESCLC Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the ESCLC market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
As per DelveInsight, the Extensive-Stage Small Cell Lung Cancer (ESCLC) therapeutics market is anticipated to increase in the coming years owing to the increasing incident case of ESSCLC, mainly due to the increase in the geriatric population, expected entry of potential premium price emerging therapies and readily uptake of currently approved immunotherapies.
Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Mechanism of Action of the Emerging Therapies
– Cytotoxic T-lymphocyte antigen 4 inhibitors
– Lysine specific demethylase 1 inhibitor
– Fucosyl GM1 ganglioside inhibitor
– Antibody-dependent cell cytotoxicity
– Toll-like receptor 7 agonists
– T lymphocyte stimulant
– Immunologic cytotoxicity
– Poly(ADP-ribose) polymerase 1 inhibitor
Extensive-Stage Small Cell Lung Cancer (ESCLC) Therapeutics Landscape
There are approx. 40+ key companies developing therapies for Extensive Stage Small Cell Lung Cancer (ESCLC). Currently, Genentech is leading the therapeutics market with its Extensive Stage Small Cell Lung Cancer (ESCLC) drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Extensive-Stage Small Cell Lung Cancer (ESCLC) Therapeutics Market include:
– Eli Lilly and Company
– Genentech
– Bristol-Myers Squibb
– Henlix Biotech
– CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
– BioNTech SE
– Xencor, Inc.
– Haihe Biopharma Co., Ltd.
– Taizhou HoudeAoke Biomedical Co., Ltd.
– Celgene
– MedImmune
– Xcovery Holding Company, LLC
– Lee’s Pharmaceutical Limited
– Merck & Co
– Astex Pharmaceuticals
And many others
Extensive-Stage Small Cell Lung Cancer (ESCLC) Therapies covered in the report include:
– LY 2510924: Eli Lilly and Company
– Tiragolumab: Genentech
– Bomedemstat: Imago BioSciences
– SYHA1807: CSPC ZhongQi Pharmaceutical Technology
– Tarlatamab: Amgen
– Socazolimab: Sorrento Therapeutics
And many more
Explore More About the Emerging Drugs and Key Companies: Extensive-Stage Small Cell Lung Cancer Pipeline Development Activities
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Extensive-Stage Small Cell Lung Cancer Current Treatment Patterns
4. Extensive-Stage Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Extensive-Stage Small Cell Lung Cancer Late-Stage Products (Phase-III)
7. Extensive-Stage Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Extensive-Stage Small Cell Lung Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Extensive-Stage Small Cell Lung Cancer Discontinued Products
13. Extensive-Stage Small Cell Lung Cancer Product Profiles
14. Key Companies in the Extensive-Stage Small Cell Lung Cancer Market
15. Key Products in the Extensive-Stage Small Cell Lung Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. Extensive-Stage Small Cell Lung Cancer Unmet Needs
18. Extensive-Stage Small Cell Lung Cancer Future Perspectives
19. Extensive-Stage Small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Extensive-Stage Small Cell Lung Cancer Therapeutic Outlook
Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.